Index of drugs

Active immunization against tetanus and diphtheria of adolescents and adults, according to the Protective Vaccine Program. Vaccine intended for primary vaccination of adults who have not been vaccinated against diphtheria and tetanus (DTP or DT vaccines) and as revaccination for adolescents aged 14 and 19 or adults who have received a full course of tetanus and diphtheria vaccination. In the case of wounds, it can be given instead of a vaccine containing tetanus toxoid (T), if a booster dose against diphtheria is indicated within this period.

1 dose (0.5 ml) of the vaccine contains not less than 40 IU. tetanus toxoid and not less than 5 IU diphtheria toxoid.

Diphtheria and tetanus vaccine, adsorbed (on hydrated aluminum hydroxide), with reduced diphtheria antigen content, compared to DTP and DT vaccines, used in children up to 6 years of age. Tokoxids are obtained by formaldehyde inactivation of bacterial toxins from cultureClostridium tetani andCorynebacterium diphtheriaewhich are then concentrated and purified. They maintain the antigenic properties of native toxins. Deprived of pathogenicity, they trigger a response from the immune system, consisting in the production of specific antibodies and activate mechanisms that allow the formation of immunological memory. The immunizing properties of the vaccine are enhanced by the adjuvant action of aluminum hydroxide. Appropriate levels of immune antibodies protecting against tetanus and diphtheria are obtained after all vaccinations (primary and booster) according to the Protective Vaccine Program.

Hypersensitivity to the active substance or vaccine excipients (thiomersal). acute infections with fever; mild infections are not a contraindication to administering a vaccine. Chronic diseases during exacerbation - the vaccination should be performed after the exacerbation of the disease. Thrombocytopenia or neurological disorders after prior administration of vaccines containing T, DT, Td, D or d antigens. If contraindications to administering diphtheria exist, only tetanus toxoid vaccine should be given. In case of any contraindications to vaccination, the risk of administering the vaccine against the risk of infection should be assessed. In the case of injury and existing contraindications to administering a vaccine or tetanus toxoid, anti-tetanus immunoglobulin should be administered immediately. Do not give intravascularly.

In patients undergoing immunosuppressive or immunodeficient treatment, the response to the vaccine may be reduced - it is recommended to postpone the vaccination to completion of therapy and / or to determine the level of anti-diphtheria and anti-tetanus antibodies after vaccination. Due to the content of thiomersal (traces), the vaccine may cause allergic reactions.

The vaccine may be used during pregnancy if there is such indication. In the first trimester, the vaccine can only be used if there is a serious risk of infection. Breast-feeding is not a contraindication to vaccination.

There may be reactions at the injection site: redness, painful swelling, pruritus, itching lymphatic infiltration. Subcutaneous nodules - granulomas, sometimes transforming into aseptic abscesses - can be extremely rare. Granules that do not disappear within 6 weeks can be the result of developing hypersensitivity to aluminum. Very rare: headache, increased body temperature, chills, excessive sweating, malaise (these symptoms usually disappear after 24-48 h); hypersensitivity and gastrointestinal disorders. Extremely rare: thrombocytopenia, renal failure and disorders of the central and peripheral nervous system.

Deep subcutaneously (in the deltoid muscle).Basic vaccination. Adults: 2 doses (primary vaccination) 4 weeks apart, the third dose (supplementary) after 6-12 months.after the second dose of primary vaccination.Revaccination. Adolescents at 14: 1 dose (second booster); in 19: 1 dose (third booster); adults with basic vaccination: give 1 dose every 10 years.Vaccination of wounded people. If the vaccination was not carried out, it was incomplete or the history of vaccination is uncertain and the risk of tetanus is high: give the tetanus diphtheria vaccine or tetanus vaccine simultaneously with human tetanus anti-tetanus immunoglobulin (250/500 IU) or horse anti-tetanus antitoxin (3000 jm), continuation of vaccination with the diphtheria-tetanus vaccine or tetanus vaccine according to the 0.1,6-month schedule; when the risk is low: only use the tetanus-diphtheria or tetanus vaccine according to the 0.1,6 month schedule. If more than 10 years have passed since the last dose of the vaccine and the risk of tetanus is high: give the tetanus-tetanus vaccine or tetanus (1 booster) simultaneously with human anti-tetanus immunoglobulin (250/500 IU) or horse anti-tetanus antitoxin (3000 IU); when the risk is low: only use the tetanus-diphtheria or tetanus vaccine (1 booster). If 5-10 years have elapsed since the last vaccine dose: only use the tetanus-diphtheria or tetanus vaccine (1 booster), regardless of the risk of tetanus. In the event that less than 5 years have elapsed since the last vaccination, the vaccine should not be used; if the risk of tetanus is particularly high, one dose of tetanus-tetanus or tetanus vaccine can be given.Pregnant women: unvaccinated or incomplete primary vaccination, which are exposed to the birth of a child in unhygienic conditions should be vaccinated in the second trimester of pregnancy; women who have received one or two doses of the vaccine before pregnancy are diagnosed should complete the vaccination during pregnancy; pregnant women who were vaccinated earlier than 10 years ago should receive a booster dose in the second trimester of pregnancy. In the first trimester, the vaccine can be used when there is a serious risk of infection.